Peptide library
Tesamorelin: evidence profile
Approved product · Randomized evidence
Read each statement within its named product, route and evidence scope. The reading exercise below helps you examine a claim; it does not choose care.
Evidence record
- Product and route
- Specified subcutaneous formulation.
- Approval scope
- Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
- Mechanism
- Stimulates growth-hormone release.
- Evidence
- A randomized trial measured visceral fat.
- Limits
- Not for weight management.
- Safety context
- Active malignancy is a contraindication.
A reading exercise
Read a tesamorelin follow-up record by separating the question of whether a measurement was made from the question of how its value was classified. Draw a simple decision path: locate the recorded value first, then find the reference definition used to interpret it. A space without an identifiable value should lead to a question about the record, not directly to the label normal. If a notation supplies a reason for the gap, retain that reason without supplying a replacement value. Check your path using an explicitly hypothetical completed entry. Explain which extra step allows that entry to receive a classification.
Questions to take away
- Where is the recorded value that would support a normal classification?
- What does the notation establish about why this entry lacks a value?
- Which additional step distinguishes the completed hypothetical entry from the unfilled one?
Sources
The dates below identify each source check. Publication of this page does not mean every source was checked again.